Abstract
Gefitinib is an anticancer drug used for the treatment of lung cancer, breast cancer and prostate cancer. A new stability indicating RP-HPLC method was proposed for the estimation of Gefitinib in pharmaceutical dosage forms (tablets). Shimadzu Model CBM-20A/20 Alite HPLC system with PDA detector and Agilent C18 column were used for the chromatographic study. Mobile phase mixture consisting of Tetra butyl ammonium hydrogen sulphate and Methanol in the ratio 50:50, v/v with a flow rate 0.8 mL/min was chosen for the chromatographic elution of Gefitinib (Detection wavelength 340 nm). The method was linear over the concentration range 0.1-80 mg/mL with linear regression equation, y = 70782x + 6171.6 (R² = 0.9999). The LOD and LOQ were found to be 0.2931 mg/mL and 0.8947 mg/mL respectively. Stress degradation studies were performed by exposing Gefitinib to various stress conditions and the method was validated as per ICH guidelines.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
